Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG
Launched by AZ JAN PALFIJN GENT · Jul 3, 2017
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • IVF/ICSI patients
- • Cycle 1, 2, 3, 4
- Exclusion Criteria:
- • PCOS
- • Endocrinological diseases
About Az Jan Palfijn Gent
AZ Jan Palfijn Gent is a leading healthcare institution located in Ghent, Belgium, dedicated to providing high-quality medical care and advancing clinical research. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and treatment methodologies across various medical disciplines. With a commitment to patient safety and ethical standards, AZ Jan Palfijn Gent collaborates with multidisciplinary teams to conduct rigorous clinical trials aimed at improving patient outcomes and contributing to the broader medical community. Its state-of-the-art facilities and experienced research staff enable the institution to effectively support the development of new therapeutic options and enhance the understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, Oost Vlaanderen, Belgium
Patients applied
Trial Officials
Wim Decleer, MD
Principal Investigator
FERTILITY CENTER AZ JAN PALFIJN
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials